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Abstract We report the molecular cloning from foetal brain of
the human potassium channel heag2. The cDNA encodes a pro-
tein of 988 amino acids, 73% identical to heag1. Heag2 is ex-
pressed in the brain, but is also found in a range of tissues
including skeletal muscle. In oocytes, the channel is a non-in-
activating outward recti¢er, with dependence of activation rate
on holding potential. Compared with heag1, the conductance^
voltage curve for heag2 was shifted to the left, the voltage
sensitivity was less, activation kinetics were di¡erent, and the
sensitivity to terfenadine was lower. The heag2 channel may
have important physiological roles. - 2002 Published by Else-
vier Science B.V. on behalf of the Federation of European Bio-
chemical Societies.
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1. Introduction
Potassium channels have key roles in setting membrane
potentials, action potential repolarisation and neuronal ¢ring
frequency. Consequently they are of vital importance in neu-
rotransmitter and hormonal release, cardiac function, as well
as cell cycling and development. These channels are also of
great importance as sites of drug action, and are the sites of
numerous pathologies such as inherited disorders [1]. Potassi-
um channels comprise several families [2] : two-transmem-
brane inward recti¢ers, four-transmembrane ‘twin-pore’ chan-
nels, and six-transmembrane voltage-dependent channels
which include Shaker, KvLQT and ether-a-go-go channel
families.
The ether-a-go-go family is characterised by long N- and C-
terminal intracellular tails, and is subdivided into eag, elk and
erg subfamilies. Within this family, there are now known to be
a total of eight genes in rat [2,3] : eag1, eag2, elk1, elk2, elk3,
erg1, erg2, erg3. The last member to be cloned, rat eag2, was
obtained only recently [4,5].
The erg subfamily [3] is characterised by fast activation,
very fast inactivation and inward recti¢cation. Erg channels
are widely expressed, including the brain and heart, where
cardiac herg1 underlies the IKr current in the heart and its
dysfunction can lead to dangerous arrhythmias. In contrast,
the eag subfamily [3] is characterised by outward recti¢cation
without inactivation; the (slow) activation kinetics depend on
holding potential (‘Cole^Moore shift’) and extracellular mag-
nesium, while the channel can be blocked by intracellular
calcium. The rat eag channels are expressed predominantly
in neural tissue; cell cycle-speci¢c expression of eag1 has
been demonstrated that may be of great importance in cellular
development and tumour growth. Finally, members of the elk
subfamily [3] show electrophysiological features like eag (e.g.
elk1), or features intermediate between eag and erg (e.g. elk2),
though they do not show the Cole^Moore shift [3].
Here, we report the molecular cloning and characterisation
of the human eag2 (heag2) channel, and we have compared its
functional properties with the previously cloned [6] heag1
channel.
2. Materials and methods
2.1. Cloning of heag2
Predictions for the sequence of the human eag2 channel were
obtained using the sequence for the rat eag2 channel [4,5] in BLAST
searches against the human genome, together with subsequent analysis
using Genscan. From this, primers were designed as follows:
5P-atgccggggggcaagagagggct (sense), 5P-atcctgacatggtatctgggggggtac
(antisense) or 5P-ggcaggccagaatccagctggacatg (antisense). These prim-
ers were used in PCR reactions using a human foetal brain cDNA
library (Clontech), and products were cloned into pGEM-TEasy. Sev-
eral clones were sequenced (four completely, two partially) to check
for sequence consistency.
Heag2 and heag1 clones (the latter in pcDNA3, accession number
AJ001366 [6], gift of L. Bernheim) were subcloned into pGEMHE
(gift of O. Pongs) for expression in oocytes using EcoRI or BamHI
respectively, and a Kozak sequence inserted into heag2. After linear-
isation with NotI, capped cRNA was transcribed in vitro using the T7
promoter (Ambion MEGASCRIPT).
2.2. Tissue expression studies
A probe was constructed by PCR using bases 2215^2423 of the
heag2 sequence (probe A) in the variable domain, sequenced, and
labelled with digoxigenin-11^dUTP using the random primer method
(Roche). The probe was used to screen a multiple-tissue Northern blot
(MTN, Clontech), and labelling detected by anti-digoxigenin antibody
conjugated to alkaline phosphatase, with detection by luminescent
light emission using CSPD (Roche).
For RT-PCR expression studies, a multiple-tissue cDNA panel
(MTC, Clontech) was used in PCR reactions, using primers designed
to amplify bases 2513^3125 of the heag2 sequence using heag2-speci¢c
primers. The heag2 clone was used as positive control, and primers
against G3PDH were used to check standardisation of cDNA quanti-
ties. To check for speci¢city, Southern blotting was carried out against
the RT-PCR products, using a probe spanning the same bases (probe
B), prepared by the PCR digoxigenin labelling method with detection
as above.
All procedures were carried out according to the manufacturer’s
instructions.
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2.3. In vitro translation
The molecular weight of the heag2 protein was obtained using in
vitro transcription and translation of heag2 cDNA in pGEMHE. For
this, heag2 protein was made in the presence of [35S]methionine using
the Promega T7 TNT Quick coupled reticulocyte lysate system with
or without canine pancreatic microsomes. Labelled proteins were sep-
arated on a 10% SDS^polyacrylamide gel, and exposed to X-ray ¢lm.
2.4. Electrophysiology
Xenopus oocytes were injected with 1.5 ng or 7 ng RNA respectively
for either heag1 or heag2 in 50 nl, and two-electrode voltage-clamp
recordings were made at room temperature (22‡C) as previously de-
scribed [7]. Oocytes in a 50 Wl chamber were superfused (1.5 ml/min)
with solution containing 2 mM KCl, 115 mM NaCl, 10 mM HEPES,
1.8 mM CaCl2, pH 7.2. Cells were held at 380 mV, and leak and
capacity subtraction were carried out using 10 mV hyperpolarising
pulses applied at 0.1 Hz. From the same holding potential, test depo-
larisations (500 ms duration) were applied (0.1 Hz) in order to con-
struct current^voltage (I^V) relationships. For heag2, ¢ts to the cur-
rent by a Boltzmann function showed deviations, using IV =
(V3Er)Gmax/(1+exp((V0:53V)/k)), reversal potential Er=398.5 mV.
This was apparently because of appreciable heag2 currents at the
holding potential; instead we ¢tted to IV3I3803(I3803I390)(V+80)/
10 (currents IV , I380, I390 at voltages V, 380 mV, 390 mV parame-
terised as above) to correct for heag2 current at the holding potential
and the subtraction procedure used; good ¢ts were then obtained.
Student’s t-test was used to test for signi¢cance, and means
SS.E.M. are shown.
3. Results
3.1. Cloning and primary structure
We obtained a heag2 clone containing an open reading
frame of 2967 bases, corresponding to a protein of 988 amino
acids (Fig. 1), taking the start methionine in the homologous
position as in rat eag2 [4,5]. A BLAST search of the human
genome with the heag2 sequence showed that the correspond-
ing gene (KCNH5) is located on chromosome 14 at 14q23.1,
and the coding sequence comprises 11 exons spanning 338 kb
of genomic sequence. The heag2 cDNA sequence was identi-
cal to that of the corresponding exons of the genomic se-
quence, except for one base at position 2577 (counting from
the start codon) where the genomic sequence has A instead of
G, without however altering the corresponding amino acid.
This may be a polymorphism, although we consistently found
G in six clones that we sequenced, and also in an EST (ac-
cession number U69185). Interestingly, this EST has another
base change (G to A at heag2 position 2233), corresponding
to a possible mutation/polymorphism A745T in the protein,
although G was present in all but one of the clones sequenced
in the present study. From comparison with ESTs, the start of
the polyA signal is apparently located at base 3200.
The heag2 channel protein has a predicted molecular weight
of 112 kDa and isoelectric point of 7.5. In vitro transcription
and translation con¢rmed (Fig. 2C) this molecular weight,
where a band of approximately 115 kDa was observed. In
the presence of microsomes, where N-glycosylation is able to
occur, the molecular weight was very similar, implying the
absence of marked glycosylation, even though the heag2 se-
quence displays two consensus sites for N-glycosylation at
extracellular locations (Fig. 1). Protein bands were also seen
at around 105 kDa and 65 kDa, which might correspond to
degradation products, or proteins starting from a more down-
stream methionine.
Heag2 channel protein is 73% identical to heag1, di¡ering
Fig. 1. Sequence alignment of heag1 and heag2 channels. The positions of the characteristic domains are marked. These include the PAS do-
main, the core channel transmembrane helices, S1^S6 and the pore P region, the cyclic nucleotide binding region, cNBD, the calcium-dependent
calmodulin binding region, CaM, the tetramerisation CAD domain, and a leucine zipper region, LZ. A variable domain (VD) between heag1
and heag2 is also shown. For heag2, the intracellular consensus sites for cAMP/cGMP phosphorylation (D) and for protein kinase C phos-
phorylation (8) are marked, as are the extracellular consensus sites for N-glycosylation (a). The arrow marks the position for alternative splic-
ing; the splice variant terminates four amino acids after the position shown. We have deposited the sequences at GenBank, accession numbers
AF472412 and AF493798. The 2233A polymorph was used for expression studies.
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mainly at a C-terminal region of some 104 amino acids, VD
(Fig. 1). In common with other members of the ether-a-go-go
family, heag2 possesses conserved domains (PAS, cNBD,
CAD domains) characteristic of this family [8^10] (Fig. 1).
There is also a calmodulin binding domain [11,12], indicating
that heag2 is sensitive to intracellular calcium block, as for rat
eag1.
One of the heag2 clones sequenced was a splice variant with
exon 10 missing (Fig. 1), resulting in a shorter protein (611
amino acids), truncated within the cNBD region. Its proper-
ties were not investigated further here; however, it may be a
channel that is non-functional on its own, similar in that
respect to the ‘HergUSO’ channel [13], which is also alterna-
tively spliced in the cNBD.
3.2. Heag2 RNA tissue expression
In RT-PCR studies of tissue distribution of heag2 (Fig.
2A), after 30 cycles of PCR the strongest signal was seen
predominantly in brain, the next strongest in skeletal muscle,
and expression was also detected in heart, placenta, lung,
liver, and at low levels in kidney. Continuing the PCR for
four further cycles also showed clear signals in kidney and
pancreas (data not shown). These general features were con-
¢rmed by repeating the analysis on a second, independent
MTC panel. There was a similar pattern of localisation in a
Southern blot, con¢rming the speci¢city of the RT-PCR re-
actions. In Northern blots (Fig. 2B), RNA transcripts at ap-
proximately 1.4 kb and 6.8 kb were observed in heart and
skeletal muscle. The smaller-sized transcript may be a splice
variant, as previously suggested for rat eag2 [4]. Surprisingly,
no transcript was seen in whole brain, reminiscent of a similar
situation for rat eag2 [4], where only very weak signals were
seen for whole brain in Northern blot, even though other data
showed strong expression in various brain regions.
3.3. Functional studies
RNA for heag2 was expressed in oocytes, and voltage-
clamp recordings of expressed currents were made. Currents
for heag2, like heag1, were non-inactivating, characteristic
[4^6,11,14] of eag channels (Fig. 3A,B), and I^V curves for
heag1 and heag2 (Fig. 3C,D) showed outward recti¢cation.
Heag2 currents activated at more negative potentials than
for heag1, as can also be seen from G^V plots (Fig. 3E). There
was a leftward shift for heag2 as compared with heag1; fur-
thermore, the voltage sensitivity was less steep for heag2, re-
£ecting less voltage-sensitive transitions to the open state for
heag2. More speci¢cally, mean V0:5 was 311.4S 3.4 mV for
heag2 (n=17), signi¢cantly di¡erent (P6 0.05) from the value
for heag1 (+10.1S 1.4 mV, n=20), while k was 34.7S 2.0 mV
for heag2, again signi¢cantly di¡erent (P6 0.05) from that for
heag1 (17.2 S 1.2 mV). Plots of activation time (time for 20 to
80% of maximal current) versus test potential are shown in
Fig. 3F; it is clear that activation times are signi¢cantly slow-
er for heag2 than for heag1.
The activation rate depends on holding potential for both
heag2 and heag1 (Fig. 4A,B); activation is faster for more
positive holding potentials (Cole^Moore shift). At ¢rst glance
the heag1 currents shown in Fig. 4B appear to activate more
slowly than those for heag2 in Fig. 4A, at least at hyperpo-
larised potentials. However, closer analysis shows that in con-
trast to heag2 currents, the heag1 currents appear slower be-
cause they are initially sigmoidal, with an initial lag in channel
opening, but that the subsequent time course (i.e. t2080%) is in
fact faster for heag1 (Fig. 4C), at least for holding potentials
in the range 3100 mV to 360 mV. The voltage dependence of
t2080% (Fig. 4C) is steeper for heag1 than for heag2, and
shows saturation. Since the Cole^Moore shift is likely due
to voltage-dependent shifts in occupation of two or more
closed states, the transitions between closed states seem to
be less voltage-sensitive for heag2 than for heag1.
Heag2 and heag1 currents were little a¡ected by TEA,
1 mM, and partially blocked at 10 mM (Fig. 5A,B). The
IC50 for both channels was somewhat greater than 10 mM
(Fig. 5E). The fact that TEA can produce a block is consistent
Fig. 2. Expression of heag2: tissue distribution and protein translation. A: RT-PCR was carried out for various human tissues using heag2-spe-
ci¢c primers (top) or GAPDH primers (bottom). A control PCR is also shown using heag2 cDNA as template. The ¢gure shows analysis by
agarose gel. A Southern blot of the gel was made using a heag2-speci¢c probe (probe B) (middle). B: Northern blot of human RNA for vari-
ous tissues, using a heag2-speci¢c probe (probe A). The arrows show the positions of the two bands. C: In vitro transcription and translation
of heag2 using rabbit reticulocyte, in the presence or absence of microsomes. 35S-labelled protein was analysed by SDS gel.
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with the potassium channel nature of these proteins. The anti-
histamine terfenadine at 1 WM had no e¡ect on heag currents,
while 10 WM terfenadine produced inhibition (Fig. 5C,D). The
extent of the block by terfenadine was signi¢cantly greater
(P6 0.05) for heag1 than for heag2 (Fig. 5E); the IC50 for
heag1 was about 10 WM.
4. Discussion
The heag2 channel is the eighth human channel of the
ether-a-go-go family to be cloned, completing this family of
genes in human. RNA for this channel was found in brain
and skeletal muscle, as for heag1 [6,15], although it was also
found at lower levels throughout a range of other tissues. The
primary structural features and domains of the heag2 se-
quence are similar to those of heag1, except for a variable
stretch in the C-terminal region (VD domain, Fig. 1). As
for heag1, the heag2 channel is characterised by outward rec-
ti¢cation without inactivation, and slow activation; the acti-
vation kinetics depend on holding potential.
The G^V curves showed that the voltage for half-maximal
activation was shifted to the left for heag2 as compared with
heag1, as also occurs for the rat eag channels [4]. The G^V
curves were also steeper for heag1, re£ecting steeper voltage
sensitivity of channel opening. Furthermore, activation ki-
netics di¡ered between the two channels, suggestive of steeper
voltage sensitivity also between closed states for heag1. By
analogy with other voltage-dependent ion channels, the S4
region is the voltage sensor [16], and so one might have ex-
pected di¡erences in S4 between the two channels. However,
Fig. 3. Functional expression of heag2 and heag1 in oocytes. Examples of potassium currents are shown for heag2 (A) and heag1 (B) during a
series of depolarising steps from 380 mV to the potentials shown. Mean normalised (Inorm) I^V curves are shown for heag2 (C) and heag1 (D)
(n=17^20). The corresponding conductance^voltage (G^V) curves are shown (E) for heag2 (F) and heag1 (b). The mean activation times,
t2080%, are shown (F) for heag2 (F) and heag1 (b) ; *P6 0.05.
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the S4 region is identical between heag1 and heag2, and there-
fore other, as yet unknown, molecular regions of the protein
must contribute to these di¡erences in activation processes.
Residues in the S4^S5 linker have already been implicated
in deactivation kinetics for other channels in the ether-a-go-
go family [17,18], but there is only one amino acid di¡erence
between heag1 and heag2 in this linker, and our mutational
studies (unpublished data) have shown that this residue is not
responsible for changes in I^V curves. Di¡erences in activa-
tion properties are likely due to di¡erences in the N- and/or
C-terminal regions of these channels.
Both heag1 and heag2 channels were weakly sensitive to
TEA, as already found for rat eag channels [4,5]. A range
of compounds have been found to block herg channels, in-
cluding class III antiarrhythmics, antihistamines, antibiotics,
antipsychotics and gastrointestinal prokinetic drugs [19]. In
the present paper, we showed that the antihistamine terfena-
dine blocked both heag1 and heag2 channels, although with
greater sensitivity for heag1. The IC50 (around 10 WM) for
heag1 is much larger than for herg channels (approx. 200
nM [20]). Although the corresponding pore-facing residues
implicated in terfenadine block for herg [19] are identical to
those in both heag1 and heag2, the extent of block is corre-
lated with the extent of inactivation [21], which is marked for
herg but absent for heag1 and heag2. Di¡erences in sensitivity
to blocking drugs between heag1 and heag2 are probably due
to one or more of the seven amino acids that di¡er between
heag1 and heag2 in the P and S6 regions, even though these
may not face the pore, as also occurs for herg [22].
The physiological role of heag2 channels is currently un-
known. However, the heag1 channel is implicated in cell
cycle-speci¢c myotube fusion [6], and interestingly heag2
was found in skeletal muscle. Furthermore, cell cycle-speci¢c
expression of eag1 has been shown to be important in cellular
development and tumour growth [15,23], and a similar phys-
iological role of heag2 in the cell cycle may also be of impor-
tance. The cellular location of heag1 and heag2 predominantly
in the brain points to important physiological processes in
brain function. The ¢nding of heag2 in the heart was unex-
pected and deserves further investigation, but may perhaps be
due to a non-functional splice variant (cf. HergUSO [13]).
After the present work was independently completed, an
interesting paper [24] appeared which also reported the clon-
ing and functional expression of heag2. The present paper
Fig. 4. Dependence of heag currents on holding potential. Examples of potassium currents for heag2 (A) and heag1 (B) are shown for depolar-
ising steps to +40 mV from holding potentials of 3130 mV to 360 mV. The corresponding activation times (t2080%) are plotted (C) against
holding potential, Vh, for heag2 (F) and heag1 (b), and the means are given for ¢ve to seven cells; *P6 0.05.
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provides new, complementary information as follows. Here
we have studied and described the tissue distribution of
heag2, in vitro translation, as well as the primary amino
acid structural features as compared with heag2 (as well as
a splice variant); these areas were not addressed by Schonherr
et al. [24]. The present paper describes functional expression
in oocytes, but our experiments were di¡erent in several re-
spects from those in [24]. Thus for I^V curves we used phys-
iological potassium solutions and activation studies rather
than high potassium and deactivation studies. Although our
results for the slope factor k of Boltzmann ¢ts to the G^V
curves were qualitatively similar to those of [24] (heag1 two
times steeper than heag2), our results for V0:5 were di¡erent.
For V0:5 we observed a shift to the left for heag2 as compared
with heag1, consonant with results for rat eag channels [4],
but di¡ering from the rightwards shift reported in [24]. For
the study of hyperpolarising voltages on the kinetics of acti-
vation, in contrast to [24], we carried out experiments in the
absence of magnesium which of course itself a¡ects kinetics,
and we presented our results directly in terms of activation
times rather than indirectly in terms of the model-dependent
parameters used in [24]. Our data show the presence of the
Cole^Moore shift for heag2 in the absence of magnesium, and
suggest a steeper voltage sensitivity between closed states for
heag1 than for heag2. We tested pharmacological blockers
with oocytes rather than with mammalian cells used in [24],
and we found a greater degree of block by TEA (10 mM) than
in [24]. Terfenadine (not tested in [24]) showed lower sensitiv-
Fig. 5. Pharmacology of heag channels. TEA was applied during repetitive stimulation to +40 mV from a holding potential of 380 mV. Exam-
ple recordings are shown for the application of TEA to heag2 (A) and heag1 (B) and for the application of terfenadine to heag2 (C) and
heag1 (D). Drugs were applied during the period shown by the bar at the concentrations shown, followed by washing. Mean values are shown
(E) for heag2 (shaded columns) and heag1 (unshaded) (n=3 throughout, except for terfenadine at 1 WM, n=2); *P6 0.05.
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ity for heag2, qualitatively, though not quantitatively, similar
to quinidine [24]. Finally, the clone described in [24] displays
the A745T polymorphism which we have already referred to
(see Section 3).
In summary, in this paper we have cloned and characterised
the last member of the ether-a-go-go family, heag2, and com-
pared its functional properties with heag1. It will be interest-
ing to determine the reasons, at the molecular level, for the
observed di¡erences in functional properties between these
two channels.
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